trial_id stringlengths 11 11 | source stringclasses 3
values | subsidiary stringlengths 2 68 | sponsor stringlengths 2 105 | official_title stringlengths 16 598 ⌀ | success_prediction float64 0 1 | economic_effect float64 0 1 | duration_prediction float64 -6.13 18.5k | success_composite float64 0.01 1 |
|---|---|---|---|---|---|---|---|---|
NCT00000145 | listed | Bausch & Lomb Incorporated | Bausch & Lomb Incorporated | Age-Related Eye Disease Study (Areds) | 0.91 | 0.52 | 2,626 | 0.760205 |
NCT00000382 | listed | Rochester | University of Rochester | Preventive Intervention For Maltreated Infants | 0.93 | 0.49 | 1,307 | 0.763312 |
NCT00000394 | listed | GW | George Washington University | A Controlled Trial Of Acupuncture For Carpal Tunnel Syndrome | 0.74 | 0.38 | 4,942 | 0.572433 |
NCT00000395 | listed | UAB "AGA" | University of Alabama at Birmingham | Mechanisms Of Antifolate Efficacy In Arthritis | 0.93 | 0.56 | 6,253 | 0.735272 |
NCT00000407 | listed | UAB "AGA" | University of Alabama at Birmingham | Improving Vocational Outcomes In Arthritis | 0.79 | 0.4 | 5,908 | 0.60251 |
NCT00000412 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | Prevention Of Osteoporosis After Cardiac Transplantation | 0.93 | 0.61 | 880 | 0.809563 |
NCT00000460 | listed | UAB "AGA" | University of Alabama at Birmingham | Training Levels Comparison (Tlc) Trial In Patients With Coronary Heart Disease | 0.09 | 0.03 | 5,915 | 0.033017 |
NCT00000497 | listed | United HealthCare of Mississippi, Inc | University of Mississippi Medical Center | null | 0.93 | 0.5 | 1,062 | 0.769593 |
NCT00000572 | listed | Intermountain Medical Group, Inc | Intermountain Health Care, Inc. | Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome | 0.91 | 0.54 | 2,569.88 | 0.784992 |
NCT00000577 | listed | Hershey Outpatient Surgery Center, L.P. | Milton S. Hershey Medical Center | Asthma Clinical Research Network (Acrn) | 0.13 | 0.45 | 6,291 | 0.258939 |
NCT00000625 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Phase Ii/Iii Trial Of Monotherapy Vs. Combination Therapy With Nucleoside Analogs In Hiv-Infected Persons With Cd4 Cells Of 200-500/Mm3 | 0.95 | 0.77 | 1,095 | 0.855402 |
NCT00000626 | listed | Amgen | Amgen | Phase Ii Study Of Filgrastim (G-Csf) Plus Abvd In The Treatment Of Hiv-Associated Hodgkin'S Disease | 0.94 | 0.54 | 1,095 | 0.771031 |
NCT00000627 | listed | Pfizer | Pfizer | Pilot Study To Determine The Feasibility Of Fluconazole For Induction Treatment And Suppression Of Relapse Of Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome | 0.94 | 0.58 | 8,036 | 0.695482 |
NCT00000635 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Treatment Of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease In Patients With Aids: Open Label Pilot Study Of Topical Trifluridine | 0.93 | 0.53 | 8,036 | 0.672679 |
NCT00000637 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Dideoxyinosine (Ddi) Versus Azt Plus Ddi In Symptomatic Hiv-Infected Children | 0.95 | 0.75 | 8,036 | 0.820722 |
NCT00000638 | listed | Lederle S.L. | Lederle Laboratories | Prophylaxis Against Tuberculosis (Tb) In Patients With Human Immunodeficiency Virus (Hiv) Infection And Confirmed Latent Tuberculous Infection | 0.94 | 0.55 | 8,036 | 0.68522 |
NCT00000640 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Comparative Study Of Dapsone / Trimethoprim And Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole In The Treatment Of Mild-To-Moderate Pcp In Patients With Aids | 0.94 | 0.57 | 8,037 | 0.753449 |
NCT00000644 | listed | Abbott | Abbott | A Phase Ii Safety And Efficacy Study Of Clarithromycin In The Treatment Of Disseminated M. Avium Complex (Mac) Infections In Patients With Aids | 0.92 | 0.53 | 4,133 | 0.731175 |
NCT00000651 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double Blind, Comparative Study Of Dideoxycytidine (Ddc) Alone Or Ddc/Azt Combination Versus Zidovudine (Zdv) Alone In Patients With Hiv Infection Who Have Received Prior Zdv Therapy | 0.94 | 0.57 | 8,036 | 0.753453 |
NCT00000655 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Study Of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) For The Treatment Of Pneumocystis Carinii Pneumonia In Aids Patients | 0.92 | 0.54 | 1,095 | 0.75963 |
NCT00000656 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I/Ii, Open Label Study To Evaluate The Antiviral Potential Of Combination Zidovudine And 2' 3'-Dideoxyinosine (Didanosine) In Patients With Asymptomatic Hiv Disease | 0.95 | 0.76 | 8,037 | 0.780286 |
NCT00000657 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Comparison Of 2',3'-Dideoxyinosine (Didanosine, Ddi) And Zidovudine In Therapy Of Patients With The Aids Dementia Complex | 0.95 | 0.73 | 8,037 | 0.796336 |
NCT00000658 | delisted | Schering-Plough A/S | Schering-Plough | A Phase Iii Randomized Trial Of Low-Dose Versus Standard-Dose Mbacod Chemotherapy With Rgm-Csf For Treatment Of Aids-Associated Non-Hodgkin'S Lymphoma | 0.95 | 0.54 | 8,037 | 0.748888 |
NCT00000659 | listed | BIOGEN INC | Biogen | A Phase Ii Trial Of Rscd4 And Azt In Patients With Aids Or Advanced Aids Related Complex (Arc) | 0.08 | 0.1 | 4,150 | 0.105132 |
NCT00000660 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase I Study Of Weekly Oral Vp-16 For Aids-Associated Kaposi'S Sarcoma | 0.94 | 0.62 | 8,037 | 0.726699 |
NCT00000662 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Treatment Ind For Retrovir Brand Zidovudine (Azt) Therapy Of Pediatric Patients With Hiv Disease | 0.79 | 0.06 | 6,208 | 0.440818 |
NCT00000667 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I/Ii Dose Escalation Study Of Intradermal Gp160 To Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses And Immunogenicity In Asymptomatic Hiv Seropositive Patients With More Than 400 Cd4+ Cells | 0.92 | 0.23 | 8,037 | 0.585464 |
NCT00000669 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety And Pharmacokinetics Study Of 2',3'-Dideoxyinosine (Ddi) Administered Twice Daily To Infants And Children With Aids Or Symptomatic Hiv Infection | 0.92 | 0.58 | 3,220 | 0.72802 |
NCT00000671 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Efficacy Study Comparing 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine Therapy Of Patients With Hiv Infection Who Have Been On Long Term Zidovudine Treatment | 0.93 | 0.57 | 4,150 | 0.750452 |
NCT00000672 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Efficacy Study Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) Administered Orally Twice Daily To Zidovudine Intolerant Patients With Aids Or Aids-Related Complex | 0.93 | 0.57 | 4,150 | 0.750452 |
NCT00000674 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Pilot Study Of Oral Clindamycin And Pyrimethamine For The Treatment Of Toxoplasmic Encephalitis In Patients With Aids | 0.94 | 0.54 | 4,581 | 0.699422 |
NCT00000676 | listed | Pfizer | Pfizer | Randomized Comparative Study Of Fluconazole Versus Clotrimazole Troches In The Prevention Of Serious Fungal Infection In Patients With Aids Or Advanced Aids-Related Complex. (A Nested Study Of Actg 081) | 0.95 | 0.6 | 8,036 | 0.769415 |
NCT00000677 | delisted | Schering-Plough A/S | Schering-Plough | Sch 39304 As Therapy For Acute Cryptococcal Meningitis In Hiv-Infected Patients Followed By Maintenance Therapy | 0.92 | 0.52 | 2,061 | 0.716602 |
NCT00000686 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety Study Of Bmy-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [D4T]) Administered Four Times Daily To Azt-Intolerant Patients With Aids Or Aids-Related Complex | 0.07 | 0.23 | 3,220 | 0.123745 |
NCT00000721 | listed | BIOGEN INC | Biogen | An Escalating Dose Tolerance Trial Of Bg8962 (Rcd4) In Patients Who Are Hiv Antibody Positive | 0.92 | 0.33 | 731 | 0.666348 |
NCT00000737 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I/Ii Study To Evaluate Single Agent And Combination Therapy With Megestrol Acetate And Dronabinol For The Treatment Of Hiv-Wasting Syndrome | 0.93 | 0.64 | 3,219 | 0.75425 |
NCT00000738 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Randomized, Double-Blind, Placebo-Controlled Trial Of Nimodipine For The Neurological Manifestations Of Hiv-1 | 0.95 | 0.57 | 8,038 | 0.715294 |
NCT00000741 | listed | Upjohn Inc | Upjohn | A Controlled Randomized Trial To Study The Efficacy Of Adjunctive Methylprednisolone For The Treatment Of Pneumocystis Carinii Pneumonia (Pcp) In Pediatric Aids Patients | 0.12 | 0.09 | 8,038 | 0.121806 |
NCT00000742 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Concentration-Controlled Trial To Assess The Safety, Tolerance, Pharmacokinetics And Development Of Decreased Hiv-1 Susceptibility To The Combination Of Atevirdine Mesylate (U-87201E), Zidovudine (Azt), And Didanosine (Ddi) | 0.95 | 0.53 | 8,038 | 0.701612 |
NCT00000743 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I, Dose-Escalating Safety And Tolerance Study Of Scd4-Pe40 In Hiv-Infected Persons | 0.93 | 0.55 | 731 | 0.747298 |
NCT00000744 | listed | Pfizer | Pfizer | A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo For Primary And Secondary Prophylaxis Of Mucosal Candidiasis In Hiv-Infected Women | 0.93 | 0.61 | 8,037 | 0.700038 |
NCT00000745 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.92 | 0.19 | 8,038 | 0.571559 |
NCT00000748 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Comparative, Prospective Study Of Daily Trimethoprim / Sulfamethoxazole (Tms) And Thrice-Weekly Tms For Prophylaxis Against Pcp In Hiv-Infected Patients | 0.94 | 0.55 | 1,062 | 0.792395 |
NCT00000750 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Study To Evaluate The Safety, Tolerance, And Efficacy Of Early Treatment With Zidovudine (Azt) In Asymptomatic Infants With Hiv Infection | 0.94 | 0.53 | 1,062 | 0.785555 |
NCT00000752 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Management Of Hiv-Infected Patients At Risk Of Recurrent Purulent Sinusitis: Role Of Anti-Inflammatory, Antibacterial, And Decongestant Prophylaxis | 0.13 | 0.42 | 8,031 | 0.222872 |
NCT00000753 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Concentration-Targeted Multidose Study Of Atevirdine Mesylate ( U-87201E ), Azt, And Ddi Or Ddc | 0.95 | 0.55 | 731 | 0.758699 |
NCT00000754 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Phase Ii Study Of Two Doses Of Interferon Alfa-2A (Ifn Alfa-2A) In Combination With Zidovudine (Azt) And Dideoxycytidine (Ddc) Versus Azt And Ddc Only In Patients With Hiv Infection And Less Than 400 Cd4 Cells/Mm3 | 0.95 | 0.57 | 8,038 | 0.741605 |
NCT00000755 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I/Ii Trial Of Vaccine Therapy Of Hiv-1 Infected Individuals With 50-500 Cd4 Cells/Mm3 | 0.94 | 0.58 | 8,038 | 0.713013 |
NCT00000757 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.92 | 0.18 | 8,038 | 0.568083 |
NCT00000765 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pilot Study To Evaluate The Efficacy Of Zidovudine In Preventing Cd4+ Lymphocyte Decline In Patients With Primary Hiv Infection. (One Treatment Arm Receives Placebo) | 0.93 | 0.55 | 8,031 | 0.679542 |
NCT00000770 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Comparative Study Of A Combination Of Zidovudine, Didanosine, And Double-Blinded Nevirapine Versus A Combination Of Zidovudine And Didanosine | 0.95 | 0.74 | 8,038 | 0.799752 |
NCT00000772 | listed | ICN Pharmaceuticals, Inc. | ICN Pharmaceuticals | A Phase I Open-Label Study Of The Safety, Tolerance, And Pharmacokinetic Interactions Of Combination Didanosine And Ribavirin In Hiv-Positive Individuals | 0.91 | 0.44 | 8,031 | 0.669745 |
NCT00000781 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, And Triple-Drug Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3) | 0.95 | 0.74 | 8,038 | 0.799752 |
NCT00000789 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; D4T) In Children With Hiv Infection | 0.95 | 0.75 | 8,038 | 0.803172 |
NCT00000791 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Ii Double-Blind Study Of Two Doses Of Sc-49483 In Combination With Zidovudine (Zdv) Versus Zdv | 0.93 | 0.55 | 8,031 | 0.723394 |
NCT00000799 | listed | Gilead Sciences | Gilead Sciences | Hpmpc (Cidofovir) Peripheral Cmv Retinitis Trial Protocol | 0.94 | 0.52 | 4,748 | 0.69949 |
NCT00000800 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Methadone Effects On Zidovudine (Zdv, Azt) Disposition | 0.92 | 0.36 | 731 | 0.676609 |
NCT00000807 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase Ii Evaluation Of Low-Dose Oral Etoposide For The Treatment Of Relapsed Or Progressed Aids-Related Kaposi'S Sarcoma After Systemic Chemotherapy | 0.93 | 0.67 | 242 | 0.823866 |
NCT00000811 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Phase Ii/Iii, Double-Blind, Two-Armed Study Of Micronized Atovaquone And Azithromycin (At/Az) As Compared To Trimethoprim-Sulfamethoxazole (Tmp/Smx) In The Prevention Of Serious Bacterial Infections When Used In Children Aged 3 Months To 19 Years With Hiv Infection | 0.95 | 0.67 | 730 | 0.82607 |
NCT00000812 | listed | Celgene Corporation | Celgene Corporation | A Phase I, Placebo-Controlled, Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Thalidomide In Subjects With Hiv-1 Infection | 0.93 | 0.58 | 242 | 0.766771 |
NCT00000815 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase Ii, Comparative Study Of Seroconversion Of Single-Dose And Two-Dose Measles Vaccination In Hiv-Infected And Hiv-Uninfected Children: A Multicenter Trial Of The Pediatric Aids Clinical Trials Group | 0.94 | 0.61 | 8,031 | 0.749617 |
NCT00000816 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Gradual Initiation Of Trimethoprim/Sulfamethoxazole As Primary Pneumocystis Carinii Pneumonia Prophylaxis | 0.92 | 0.54 | 830 | 0.833228 |
NCT00000819 | listed | Upjohn Inc | Upjohn | A Phase Ii Randomized, Double-Blind, Placebo-Controlled Trial To Determine The Efficacy Of Prednisone Therapy In Hiv-Associated Nephropathy (Hivan) | 0.93 | 0.52 | 1,095 | 0.75849 |
NCT00000822 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I/Ii Double-Blind Controlled Trial To Determine The Safety And Immunogenicity Of Hiv-1 Mn Rgp160 Immuno Ag Vaccine Therapy In Hiv-Infected Individuals With Greater Than Or Equal To 500/Mm3 Cd4+ T Cells And 200-400/Mm3 Cd4+ T Cells | 0.93 | 0.49 | 8,032 | 0.676556 |
NCT00000823 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter Phase Ii Double-Blind Exploratory Study To Evaluate Differences Among Various Zidovudine/Didanosine Regimens On Quantitative Measures Of Viral Burden In Relatively Early Hiv-1 Infection | 0.95 | 0.74 | 91 | 0.864039 |
NCT00000839 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Trial To Evaluate Didanosine (Ddi) In Hiv-Infected Pregnant Women | 0.94 | 0.63 | 8,032 | 0.730142 |
NCT00000953 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Evaluation Of Brovavir ( Bv-Ara-U; Sq 32,756 ) Versus Acyclovir In The Treatment Of Localized Herpes Zoster In Hiv-Infected Patients | 0.92 | 0.6 | 4,137 | 0.755093 |
NCT00000954 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase I/Ii Study Of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) And Dideoxyinosine (Ddi) Or Dideoxycytidine (Ddc) In The Treatment Of Aids-Related Kaposi'S Sarcoma | 0.95 | 0.66 | 8,032 | 0.746104 |
NCT00000955 | listed | Warner Lambert Co. | Warner Lambert - Parke Davis | Two-Stage Tuberculin (Ppd) Skin Testing In Individuals With Human Immunodeficiency Virus (Hiv) Infection | 0.94 | 0.56 | 5,082 | 0.70337 |
NCT00000956 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.93 | 0.2 | 8,038 | 0.580827 |
NCT00000960 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Randomized Placebo-Controlled Trial To Evaluate The Efficacy, Safety And Tolerance Of Oral Zidovudine (Azt) In Pregnant Hiv Infected Women And Their Infants | 0.96 | 0.53 | 8,032 | 0.751191 |
NCT00000961 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Ii Study To Evaluate The Safety, Tolerance And Efficacy Of Hyperimmune Anti-Hiv Intravenous Immunoglobulin (Hivig) And Of Zidovudine (Zdv) In Infants With Documented Hiv Infections | 0.07 | 0.1 | 8,038 | 0.079183 |
NCT00000963 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Randomized Comparative Trial Of Two Doses Of 2',3'-Dideoxyinosine (Ddi) In Children With Symptomatic Hiv Infection Who Are Either Unresponsive To Zidovudine And/Or Who Are Intolerant To Zidovudine | 0.94 | 0.65 | 8,032 | 0.763294 |
NCT00000965 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pharmacokinetics Of Total Phosphorylated Zidovudine In Mononuclear Cells From Hiv-Infected Patients | 0.53 | 0.23 | 615 | 0.394071 |
NCT00000967 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Safety And Tolerance Of Zidovudine And Interferon-Alpha In Hiv-Infected Children | 0.94 | 0.55 | 8,032 | 0.702779 |
NCT00000969 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Prospective, Randomized, Open-Label, Comparative Trial Of Dideoxyinosine (Ddi) Versus Dideoxycytidine (Ddc) In Hiv-Infected Patients Who Are Intolerant Of Or Who Have Failed Zidovudine (Azt) Therapy | 0.93 | 0.73 | 8,038 | 0.741078 |
NCT00000973 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pyrimethamine Pharmacokinetics In Hiv Positive Patients Seropositive For Toxoplasma Gondii | 0.94 | 0.37 | 8,038 | 0.641184 |
NCT00000975 | listed | Janssen Pharmaceutical | Janssen Pharmaceuticals | Pilot Study To Determine The Feasibility Of Itraconazole For Primary Treatment And Suppression Of Relapse Of Disseminated Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome | 0.94 | 0.53 | 1,095 | 0.767611 |
NCT00000977 | listed | Protein Sciences Corp. | Protein Sciences Corporation | Active Immunization Of Asymptomatic, Hiv-Infected Individuals With Recombinant Gp160 Hiv-1 Antigen: A Phase I/Ii Study Of Immunogenicity And Toxicity | 0.93 | 0.19 | 8,038 | 0.577351 |
NCT00000979 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Comparison Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine In Therapy Of Patients With Hiv Infection | 0.93 | 0.58 | 1,095 | 0.779012 |
NCT00000983 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Blinded Trial To Evaluate The Safety And Tolerance Of High Versus Low Dose Zidovudine Administered To Children With Human Immunodeficiency Virus | 0.95 | 0.54 | 1,095 | 0.776732 |
NCT00000988 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety And Pharmacokinetics Study Of Bmy-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily To Patients With Aids Or Aids Related Complex | 0.59 | 0.31 | 3,220 | 0.447545 |
NCT00000989 | delisted | Schering-Plough A/S | Schering-Plough | A Controlled, Randomized Phase Ii Study Of The Safety And Efficacy Of Combined Therapy With Ganciclovir And Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone For The Treatment Of Sight-Threatening Cytomegalovirus Retinitis In Aids Patients | 0.94 | 0.56 | 615 | 0.740674 |
NCT00001007 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter Phase I Trial To Evaluate The Safety And Pharmacokinetics Of Intravenous And Oral Zidovudine In Infants With Perinatal Human Immunodeficiency Virus (Hiv) Exposure | 0.93 | 0.52 | 3,178 | 0.713496 |
NCT00001018 | listed | Janssen Pharmaceutical | Janssen Pharmaceuticals | Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics And Dose Escalation, Efficacy, And Safety Study Of Letrazuril For Aids-Related Cryptosporidial Diarrhea | 0.92 | 0.52 | 2,061 | 0.716602 |
NCT00001024 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter, Open-Label Study Of Viral Burden In Peripheral Blood Versus Lymphoid Tissue Before And After Antiretroviral Therapy In Hiv-Infected Individuals Without Aids (Note: One Arm Receives No Treatment) | 0.94 | 0.67 | 942 | 0.77357 |
NCT00001025 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Study To Evaluate The Short-Term Clinical And Virologic Significance Of Zidovudine Resistance | 0.94 | 0.73 | 8,035 | 0.790644 |
NCT00001029 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind, Three-Arm Study Comparing Combination To Monthly Alternating Nucleoside Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3) With A Prior History Of Nucleoside Therapy | 0.94 | 0.74 | 1,095 | 0.83944 |
NCT00001035 | delisted | Schering-Plough A/S | Schering-Plough | A Phase I Pilot Study Of The Safety And Efficacy Of Interferon Alfa-2B (Ifn Alfa-2B) In Combination With Nucleoside Analog Therapy In Patients With Combined Hepatitis C (Hcv) And Advanced Human Immunodeficiency Virus (Hiv) Infections | 0.95 | 0.53 | 4,563 | 0.719349 |
NCT00001038 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Trial Of Valacyclovir Hydrochloride (Bw 256U87) Prophylaxis For Opportunistic Cytomegalovirus End-Organ Disease In Patients With Advanced Hiv Infection (< 100 Cd4+ Lymphocytes) | 0.93 | 0.52 | 4,137 | 0.750971 |
NCT00001045 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Double-Blinded, Randomized Trial Comparing Zidovudine (Azt) Versus Azt Plus Didanosine (Ddi) Versus Azt Plus Ddi Plus Nevirapine In Asymptomatic Patients On Azt Monotherapy Who Develop A Mutation At Codon 215 Of Hiv Reverse Transcriptase In Serum/Plasma Viral Rna | 0.95 | 0.7 | 8,038 | 0.78607 |
NCT00001048 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Multicenter Study Comparing Antiretroviral Therapy Alone To Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) For The Treatment Of Progressive Multifocal Leukoencephalopathy (Pml) In Human Immunodeficiency Virus (Hiv)-Infected Subjects | 0.95 | 0.66 | 1,095 | 0.817777 |
NCT00001054 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Trial To Evaluate The Pharmacokinetics, Safety, And Tolerance Of Valacyclovir Hcl In Hiv-1 Infected Children With Herpes Simplex Infections Or Varicella/Zoster Infections | 0.09 | 0.07 | 8,038 | 0.054012 |
NCT00001059 | listed | Amgen | Amgen | Comparison Study Of Liposomal Doxorubicin With Or Without Bleomycin And Vincristine For The Treatment Of Advanced Aids-Associated Kaposi'S Sarcoma | 0.95 | 0.64 | 1,095 | 0.810936 |
NCT00001061 | listed | Facet Biotech Corporation | Facet Biotech | A Phase Ii, Double-Masked, Randomized, Placebo-Controlled Evaluation Of Standard Therapy Vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (Msl 109) In The Therapy Of Aids Patients With Cytomegalovirus (Cmv) Retinitis | 0.96 | 0.54 | 8,035 | 0.737057 |
NCT00001063 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Randomized Study Of The Virologic And Immunologic Effects Of D4T Vs Zidovudine Plus D4T Vs Zidovudine Plus Ddl In Hiv-Infected Patients With Cd4 Cell Counts Between 300-600/Mm3 And Greater Than 12 Weeks Zidovudine Experience | 0.95 | 0.65 | 8,038 | 0.768968 |
NCT00001065 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Trial Of Amphotericin B Oral Suspension For Fluconazole-Resistant Oral Candidiasis In Hiv-Infected Patients | 0.94 | 0.67 | 1,095 | 0.815497 |
NCT00001066 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Comparative Study Of Combined Zidovudine-Lamivudine (3Tc) Vs. The Better Of Ddi Monotherapy Vs. Zidovudine Plus Ddl In Symptomatic Hiv-1 Infected Children | 0.94 | 0.62 | 426 | 0.808386 |
NCT00001114 | delisted | Schering-Plough A/S | Schering-Plough | A Randomized Phase Ii Trial To Determine The Safety, Tolerance, And Efficacy Of Two Doses Of Interferon Alfa-2B Combined With Didanosine In Patients With Kaposi'S Sarcoma | 0.94 | 0.66 | 8,035 | 0.766701 |
NCT00001128 | listed | GENETICS INSTITUTE, INC. | Genetics Institute | A Pilot, Proof-Of-Concept, Dose-Escalating Trial Of Recombinant Human Interleukin-12 (Rhil-12) Versus Placebo Along With Paromomycin And Azithromycin For Chronic Cryptosporidiosis In Aids | 0.09 | 0.03 | 6,176 | 0.03167 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.